Business · 04/08/1998Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Posicor Patent Extension
Summary
The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for Posicor, a human drug product, in accordance with federal regulations, following a submission to the Commissioner of Patents and Trademarks, Department of Commerce, requesting patent extension.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →